27 min listen
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update
FromASCO Guidelines
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update
FromASCO Guidelines
ratings:
Length:
7 minutes
Released:
Jan 20, 2023
Format:
Podcast episode
Description
Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive HER2-negative metastatic breast cancer based on recent evidence published in TROPiCS-02. Dr. Moy reviews how this update intersects with the previous rapid recommendation update on trastuzumab deruxtecan and future areas of research that may impact further updates to this evidence-based guideline. Read the latest update, "Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update" at www.asco.org/breast-cancer-guidelines.
Released:
Jan 20, 2023
Format:
Podcast episode
Titles in the series (100)
Practical Assessment and Management of Vulnerabilities in Older Patients Guideline: An interview with Dr. Supriya Mohile from University of Rochester on the guideline published in JCO which provides guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. To read... by ASCO Guidelines